Dr. Sue Sisley MD

Dr. Sue Sisley MD is an Arizona-based physician practicing Internal Medicine & Psychiatry.

She works as Independent Medical Director for medical cannabis license holders in 17 different states from Hawaii to Florida to New Jersey.

Sue serves as President of Scottsdale Research Institute & Principal Investigator for the only FDA-approved randomized controlled trial in the world examining safety/efficacy of whole plant marijuana in combat veterans with severe post traumatic stress disorder PTSD.

Her other areas of current IRB-approved research include supervising studies evaluating cannabis for pain management, cannabis as substitution therapy for opioids, and also a safety study looking at cannabis edibles. Dr. Sisley also awarded Govt grant as PI to build a robust nationwide medical cannabis patient registry.

Dr. Sisley holds 2 different DEA Schedule 1 Licenses

1) conduct federally-regulated cannabis research

2) supervise a DEA Schedule 1 cannabis analytical laboratory.


Dr. Sisley is on adjunct faculty at Colorado State University & Humboldt State University, and Senior Fellow at Thomas Jefferson University Lambert Center, and Co-Investigator @ University of Michigan College of Medicine, assisting their Institutes of Cannabis Research.

Dr. Sisley has been a Member of Nevada ILAC Medical Cannabis Commission for the past 3 years, outlining regulations for laboratory testing (limits on pesticides, residual solvents and other guidelines) that are currently being used as a model for other states’ medical cannabis laws. In addition to cannabis research, Dr. Sisley is practicing primary care physician providing telemedicine services to several Native American tribes within Arizona.

She serves on NIH Tribal Advisory Committee guiding them on various public health issues including cannabis safety guidelines.

Principle Investigator & Sub-I on numerous Pharma clinical trials involving Fibromyalgia, Alzheimer’s Disease, Parkinson’s Disease, Diabetes Mellitus etc

How does this speaker contribute diverse perspective?

I’m one of the few cannabis scientists in the country that holds the coveted DEA schedule 1 researcher license which allows me the “privilege“ of purchasing federally legal cannabis from the DEA/NIDA National Institute on drug abuse. I hold both a DEA researcher license and a schedule one analytical lab license. So we recently stored 8 kg of federal government cannabis to conduct various veterans’ clinical trial looking at how PTSD symptoms respond to different varieties of cannabis.

I’m one of the few female scientists in the country studying whole plant flower as a medicine. I also have the distinction of receiving one of the RARE government grants to study EFFICACY of cannabis instead of just constantly doing safety studies to uncover the harms and dangerous side effects.

I don’t own any interest in the cannabis space. I don’t own equity in grows nor dispensaries etc. I’m just focused on collecting objective data. And my research is focused only on developing flower as medicine—

Flower is the most controversial and difficult part of marijuana to medicalize, but it will be the least expensive, generic after 3 years of data exclusivity expires, and set the most precedents for botanical medicines.